Intravenous (IV) abatacept — Competitive Intelligence Brief

Intravenous (IV) abatacept (Intravenous (IV) abatacept) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CTLA-4 fusion protein; T-cell costimulation inhibitor. Area: Immunology.

phase 3 CTLA-4 fusion protein; T-cell costimulation inhibitor CD80, CD86 Immunology Small molecule

Target snapshot

Intravenous (IV) abatacept (Intravenous (IV) abatacept) — Bristol-Myers Squibb. Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous (IV) abatacept TARGET	Intravenous (IV) abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
Orencia	abatacept	Bristol-Myers Squibb	marketed	Selective T cell costimulation modulator	CD80, CD86, CD28	2005-01-01
Placebo matching with Abatacept	Placebo matching with Abatacept	Bristol-Myers Squibb	marketed	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
Double-blind Abatacept	Double-blind Abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein (T-cell co-stimulation inhibitor)	CD80, CD86
Abatacept SC	Abatacept SC	University Medical Center Groningen	phase 3	Costimulation modulator; T cell inhibitor	CD80, CD86
IV Abatacept	IV Abatacept	Rüdiger B. Müller	marketed	T-cell costimulation inhibitor	CD80/CD86
abatacept infusion	abatacept infusion	University of Minnesota	marketed	T-cell costimulation inhibitor	CD80/CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CTLA-4 fusion protein; T-cell costimulation inhibitor class)

1. Bristol-Myers Squibb · 2 drugs in this class